贝洛妥珠单抗预防多次复发艰难梭菌感染（CDI）患者再次发生 CDI 的疗效。
Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI.
机构信息
Loyola University Medical Center, Department of Medicine, Maywood, IL, USA; Edward Hines Jr., Veteran Affairs Hospital, Research Section, Infection Diseases Section, Hines, IL, USA.
University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA.
出版信息
Anaerobe. 2023 Dec;84:102788. doi: 10.1016/j.anaerobe.2023.102788. Epub 2023 Nov 4.
Among 23 patients with multiply recurrent Clostridioides difficile infection (mrCDI) who received bezlotoxumab at the end of antibiotic treatment a sustained clinical response of 91 % at 30 days and 78 % at 90 days was achieved. Bezlotoxumab administered at the end of antibiotic treatment was effective in patients with mrCDI.
在接受抗生素治疗结束时接受贝洛妥珠单抗治疗的 23 例复发性艰难梭菌感染（mrCDI）患者中，在 30 天和 90 天分别有 91%和 78%的患者获得持续的临床应答。在 mrCDI 患者中，抗生素治疗结束时给予贝洛妥珠单抗是有效的。
Zotero 插件